Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders

Neurology

Volumn 53, Issue SUPPL. 2, 1999, Pages

  Ketter, Terence A ^a   Post, R M ^b   Theodore, W H ^c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; FELBAMATE; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANTICONVULSANT THERAPY; COGNITIVE DEFECT; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; DRUG MECHANISM; EPILEPSY; HUMAN; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEIZURE;

ANTICONVULSANTS; EPILEPSY; HUMANS; MENTAL DISORDERS;

EID: 0033595496     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (288)

1. Theodore WH, Devinsky O. Epilepsy and behavior. New York: Wiley-Liss, 1991.
2. Petty F. GABA and mood disorders: a brief review and hypothesis. J Affect Disord 1995;34:275-281.
3. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 1998;55:715-720.
4. Motohashi N. GABA receptor alterations after chronic lithium administration. Comparison with carbamazepine and sodium valproate. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:571-579.
5. B receptors are up-regulated by chronic treatment with lithium or carbamazepine. GABA hypothesis of affective disorders? Eur J Pharmacol 1989; 166:95-99.
6. Bernasconi R, Martin P. Effects of antiepileptic drugs on the GABA turnover rate [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1979;307:R63.
7. Bernasconi R. The GABA hypothesis of affective illness: influence of clinically effective antimanic drugs on GABA turnover. In: Emrich HM, Aidenhoff JB, Lux HD, eds. Basic mechanisms in the action of lithium. Amsterdam: Elsevier Science, 1982:183-192.
8. Bernasconi R, Hauser K, Martin P, Schmutz M. Biochemical aspects of the mechanism of action of valproate. In: Emrich HM, Okuma T, Müller AA, eds. Anticonvulsants in affective disorders. Amsterdam: Elsevier Science, 1984:14-32.
9. Salzman C, Miyawaki EK, le Bars P, Kerrihard TN. Neurobiologic basis of anxiety and its treatment. Harv Rev Psychiatry 1993;1:197-206.
10. A receptor subtype diversity: implications for new generation hypnotic drug discovery. Sleep 1996;19:843-54.
11. Agmo A, Pruneda R, Guzman M, Gutierrez M. GABAergic drugs and conflict behavior in the rat: lack of similarities with the actions of benzodiazepines. Naunyn Schmiedebergs Arch Pharmacol 1991;344:314-322.
12. Vellucci SV, Webster RA. The role of GABA in the anticonflict action of sodium valproate and chlordiazepoxide. Pharmacol Biochem Behav 1984;21:845-851.
13. Petersen EN, Lassen JB. A water lick conflict paradigm using drug experienced rats. Psychopharmacology (Berl) 1981; 75:236-239.
14. Commissaris RL, Hill TJ, McMiller LV Jr, Kleinsorge RJ. Initial subsensitivity to anxiolytic treatments on conflict behavior in rats: parametric studies across drug classes. Pharmacol Biochem Behav 1995;51:391-396.
15. Singh L, Field MJ, Ferris P, et al. The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. Psychopharmacology (Berl) 1996;127:1-9.
16. Myslobodsky M, Feldon J, Lerner T. Anticonflict action of sodium valproate. Interaction with convulsant benzodiazepine (Ro 5-3663) and imidazodiazepine (Ro 15-1788). Life Sci 1983;33:317-321.
17. Liljequist S, Engel JA. Reversal of the anti-conflict action of valproate by various GABA and benzodiazepine antagonists. Life Sci 1984;34:2525-2533.
18. Clineschmidt BV. Effect of the benzodiazepine receptor antagonist Ro 15-1788 on the anticonvulsant and anticonflict actions of MK-801. Eur J Pharmacol 1982;84:119-121.
19. Hines G. Lithium effects on position learning with exploratory and aversive goal-box conditions. Pharmacol Biochem Behav 1985;22:695-698.
20. Almeida RN, Leite JR. Effects of acute or chronic carbamazepine on experimentally-induced conflict in the rat. Psychopharmacology (Berl) 1990;100:227-229.
21. Shephard RA. Valproate enhances fluid consumption suppressed by shock or neophobia, but not by partial satiation or d-amphetamine, in rats. Life Sci 1988;43:897-904.
22. Corbett R, Fielding S, Cornfeldt M, Dunn RW. GABAmimetic agents display anxiolytic-like effects in the social interaction and elevated plus maze procedures. Psychopharmacology (Berl) 1991;104:312-316.
23. Sherif F, Oreland L. Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in socially isolated rats. Behav Brain Res 1995;72:135-140.
24. Sherif F, Harro J, el-Hwuegi A, Oreland L. Anxiolytic-like effect of the GABA-transaminase inhibitor vigabatrin (gamma-vinyl GABA) on rat exploratory activity. Pharmacol Biochem Behav 1994;49:801-805.
25. Sherif F, Oreland L. Effects of chronic treatment with the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in rats. Behav Brain Res 1994;63:11-15.
26. Rostock A, Hoffmann W, Siegemund C, Bartsch R. Effects of carbamazepine, valproate calcium, clonazepam and piracetam on behavioral test methods for evaluation of memory-enhancing drugs. Methods Find Exp Clin Pharmacol 1989; 11:547-553.
27. Semba J, Kuroda Y, Takahashi R. Potential antidepressant properties of subchronic GABA transaminase inhibitors in the forced swimming test in mice. Neuropsychobiology 1989; 21:152-156.
28. Aley KO, Kulkarni SK. GABA-mediated modification of despair behavior in mice. Naunyn Schmiedebergs Arch Pharmacol 1989;339:306-311.
29. Sluzewska A, Chodera A. Antidepressant effect of carbamazepine - the role of dopaminergic and noradrenergic agents. Pol J Pharmacol Pharm 1992;44:209-215.
30. Borsini F, Evangelista S, Meli A. Effect of GABAergic drugs in the behavioral 'despair' test in rats. Eur J Pharmacol 1986;121:265-268.
31. Flugy A, Gagliano M, Cannizzaro C, Novara V, Cannizzaro G. Antidepressant and anxiolytic effects of alprazolam versus the conventional antidepressant desipramine and the anxiolytic diazepam in the forced swim test in rats. Eur J Pharmacol 1992;214:233-238.
32. Eroglu L, Hizal A. Antidepressant action of lithium in behavioral despair test. Pol J Pharmacol Pharm 1987;39:667-673.
33. Barros HM, Leite JR. The effects of carbamazepine on two animal models of depression. Psychopharmacology (Berl) 1987;92:340-342.
34. Przegalinski E, Tatarczynska E, Deren-Wesolek A, Chojnacka-Wojcik E. Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors. Pharmacol Biochem Behav 1996;54:73-77.
35. Trullas R, Folio T, Young A, Miller R, Boje K, Skolnick P. 1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur J Pharmacol 1991; 203:379-385.
36. Vamvakides A. Effect of some GABA, glycine, or glutamic acid derivatives on the forced swimming test in mice. Ann Pharm Fr 1990;48:154-159.
37. Maj J, Rogōz Z, Skuza G, Jaros T. Some behavioral effects of CNQX and NBQX, AMPA receptor antagonists. Pol J Pharmacol 1995;47:269-277.
38. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th ed. Washington: American Psychiatric Association, 1994.
39. Rivinus TM. Psychiatric effects of the anticonvulsant regimens. J Clin Psychopharmacol 1982;2:165-192.
40. Twyman RE, Rogers CJ, Macdonald RL. Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital. Ann Neurol 1989;25:213-220.
41. Andersen T, Lingjaerde O. Nitrazepam (Mogadon) as a sleep-inducing agent. An analysis based on a double-blind comparison with phenobarbitone. Br J Psychiatry 1969;115:1393-1397.
42. Rickels K, Pereira-Ogan JA, Chung HR, Gordon PE, Landis WB. Bromazepam and phenobarbital in anxiety: a controlled study. Curr Ther Res Clin Exp 1973;15:679-690.
43. Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987;80:909-917.
44. Robertson MM, Trimble MR, Townsend HR. Phenomenology of depression in epilepsy. Epilepsia 1987;28:364-372.
45. Meador KJ, Loring DW, Huh K, Gallagher BB, King DW. Comparative cognitive effects of anticonvulsants. Neurology 1990;40:391-394.
46. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-151.
47. Ounsted C. The hyperkinetic syndrome in epileptic children. Lancet 1955;2:303-311.
48. Wolf SM, Forsythe A. Behavior disturbance, phenobarbital, and febrile seizures. Pediatrics 1978;61:728-731.
49. Özdirim E, Renda Y, Epir S. Effects of phenobarbita and phenytoin on the behavior of epileptic children. Adv Epileptol 1978;13:120-123.
50. Vining EP, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987;80:165-174.
51. Millichap JG, Fowler GW. Treatment of "minimal brain dysfunction" syndromes. Selection of drugs for children with hyperactivity and learning disabilities. Pediatr Clin North Am 1967;14:767-777.
52. Dale J. Psychiatric factors in barbiturate intoxication. Int Anesthesiol Clin 1966;4:389-398.
53. Tchicaloff M, Gaillard F. Some undesirable effects of anti-epileptic drugs on intellectual performance. Rev Neuropsychiatr Infant 1970;18:599-604.
54. Reynolds EH, Travers RD. Serum anticonvulsant concentrations in epileptic patients with mental symptoms. A preliminary report. Br J Psychiatry 1974;124:440-445.
55. Camfield CS, Chaplin S, Doyle AB, Shapiro SH, Cummings C, Camfield PR. Side effects of phenobarbital in toddlers; behavioral and cognitive aspects. J Pediatr 1979;95:361-365.
56. MacLeod CM, Dekabian AS, Hunt E. Memory impairment in epileptic patients: selective effects of phenobarbital concentration. Science 1978;202:1102-1104.
57. Byrne JM, Camfield PR, Clark-Touesnard M, Hondas BJ. Effects of phenobarbital on early intellectual and behavioral development: a concordant twin case study. J Clin Exp Neuropsychol 1987;9:393-398.
58. Farwell JR, Lee YJ, Hirtz DG, Sulzbacher SI, Ellenberg JH, Nelson KB. Phenobarbital for febrile seizures - effects on intelligence and on seizure recurrence. N Engl J Med 1990;322: 364-369.
59. Wolf SM, Forsythe A, Stunden AA, Friedman R, Diamond H. Long-term effect of phenobarbital on cognitive function in children with febrile convulsions. Pediatrics 1981;68:820-823.
60. Galiassi R, Lorusso S, Stracciari A, Morreale A, Procaccianti G, Baruzzi A. Withdrawal of phenobarbital and carbamazepine in epileptic patients: a preliminary neuropsychological report. Acta Neurol Scand 1986;74:59-62.
61. Chen YJ, Kang WM, So WC. Comparison of antiepileptic drugs on cognitive function in newly diagnosed epileptic children: a psychometric and neurophysiological study. Epilepsia 1996;37:81-86.
62. Schwarz JR, Grigat G. Phenytoin and carbamazepine: potential-and frequency-dependent block of Na currents in mammalian myelinated nerve fibers. Epilepsia 1989;30:286-294.
63. Diehl LW. Nil nocere. Unusual hyperkinetic syndromes following diphenylhydantoin administration. Munch Med Wochenschr 1969;111:1679-1681.
64. Franks RD, Richter AJ. Schizophrenia-like psychosis associated with anticonvulsant toxicity. Am J Psychiatry 1979;136: 973-974.
65. Ideström CM, Schalling D, Carlquist U, Sjoqvist F. Acute effects of diphenylhydantoin in relation to plasma levels. Behavioral and psychophysiological studies. Psychol Med 1972; 2:111-120.
66. Dodrill CB. Diphenylhydantoin serum levels, toxicity, and neuropsychological performance in patients with epilepsy. Epilepsia 1975;16:593-600.
67. Andrewes DG, Bullen JG, Tomlinson L, Elwes RD, Reynolds EH. A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy. Epilepsia 1986;27:128-134.
68. Gallassi R, Morreale A, Lorusso S, et al. Cognitive effects of phenytoin during monotherapy and after withdrawal. Acta Neurol Scand 1987;75:258-261.
69. Duncan JS, Shorvon SD, Trimble MR. Effects of removal of phenytoin, carbamazepine, and valproate on cognitive function. Epilepsia 1990;31:584-591.
70. Dikmen SS, Temkin NR, Miller B, Machamer J, Winn HR. Neurobehavioral effects of phenytoin prophylaxis of posttraumatic seizures. JAMA 1991;265:1271-1277.
71. Goldberg JB, Kurland AA. Dilantin treatment of hospitalized cultural-familial retardates. J Nerv Ment Dis 1970;150:133-137.
72. Dodrill CB, Troupin AS. Psychotropic effects of carbamazepine in epilepsy: a double-blind comparison with phenytoin. Neurology 1977;27:1023-1028.
73. Dodrill CB, Troupin AS. Neuropsychological effects of carbamazepine and phenytoin: a reanalysis. Neurology 1991;41: 141-143.
74. Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-422.
75. Rickels K, Chung HR, Csanalosi IB, et al. Alprazolam, diazepam imipramine, and placebo in outpatients with major depression. Arch Gen Psychiatry 1987;44:862-866.
76. Bradwejn J, Shriqui C, Koszycki D, Meterissian G. Double-blind comparison of the effects of clonazepam and lorazepam in acute mania. J Clin Psychopharmacol 1990;10:403-408.
77. Wilensky AJ, Ojemann LM, Temkin NR, Troupin AS, Dodrill CB. Clorazepate and phenobarbital as antiepileptic drugs: a double-blind study. Neurology 1981;31:1271-1276.
78. Carson MJ, Gilden C. Treatment of minor motor seizures with clonazepam. Dev Med Child Neurol 1975;17:306-310.
79. Mikkelsen B, Birket-Smith E, Bradt S, et al. Clonazepam in the treatment of epilepsy. A controlled clinical trial in simple absences, bilateral massive epileptic myoclonus, and atonic seizures. Arch Neurol 1976;33:322-325.
80. Lander CM, Donnan GA, Bladin PF, Vajda FJ. Some aspects of the clinical use of clonazepam in refractory epilepsy. Clin Exp Neurol 1979;16:325-332.
81. Ghoneim MM, Mewaldt SP, Berie JL, Hinrichs JV. Memory and performance effects of single and 3-week administration of diazepam. Psychopharmacology (Berl) 1981;73:147-151.
82. Demers-Desrosiers LA, Nestoros JN, Vaillancourt P. Acute psychosis precipitated by withdrawal of anticonvulsant medication. Am J Psychiatry 1978;135:981-982.
83. de Bard ML. Diazepam withdrawal syndrome: a case with psychosis, seizure, and coma. Am J Psychiatry 1979;136: 104-105.
84. Sironi VA, Franzini A, Ravagnati L, Marossero F. Interictal acute psychoses in temporal lobe epilepsy during withdrawal of anticonvulsant therapy. J Neurol Neurosurg Psychiatry 1979;42:724-730.
85. Zaret BS, Cohen RA. Reversible valproic acid-induced dementia: a case report. Epilepsia 1986;27:234-240.
86. Hauser P, Devinsky O, De Bellis M, Theodore WH, Post RM. Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders. Arch Neurol 1989;46:696-699.
87. Ketter TA, Malow BA, Flamini R, White SR, Post RM, Theodore WH. Anticonvulsant withdrawal-emergent psychopathology. Neurology 1994;44:55-61.
88. Lampe H, Bigalke H. Carbamazepine blocks NMDA-activated currents in cultured spinal cord neurons. Neuroreport 1990;1:26-28.
89. Post RM, Weiss SRB, Chuang DM, Ketter TA. Mechanisms of action of carbamazepine in seizure and affective disorders. In: Joffe RT, Calabrese JR, eds. Anticonvulsants in psychiatry. New York: Marcel Dekker, 1994:43-92.
90. Mai J, Chojnacka-Wojcik E, Lewandowska A, Tatarczynska E, Wiczynska B. The central action of carbamazepine as a potential antidepressant drug. Pol J Pharmacol Pharm 1985; 37:47-56.
91. Post RM, Ketter TA, Denicoff K, et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl) 1996;128:115-129.
92. Brown SW, McGowan ME, Reynolds EH. The influence of seizure type and medication on psychiatric symptoms in epileptic patients. Br J Psychiatry 1986;148:300-304.
93. Dalby MA. Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971;12:325-334.
94. Rodin EA, Rim CS, Kitano H, Lewis R, Rennick PM. A comparison of the effectiveness of primidone versus carbamazepine in epileptic outpatients. J Nerv Ment Dis 1976;163:41-46.
95. Reid AH, Naylor GJ, Kay DS. A double-blind, placebo controlled, crossover trial of carbamazepine in overactive severely mentally handicapped patients. Psychol Med 1981;11: 109-113.
96. Hermann BP, Melyn M. Effects of carbamazepine on interictal psychopathology in TLE with ictal fear. J Clin Psychiatry 1984;45:169-171.
97. Langee HR. A retrospective study of mentally retarded patients with behavioral disorders who were treated with carbamazepine. Am J Ment Retard 1989;93:640-643.
98. Rubenstein JL, Steiner H, Walton C. Depression, episodic behavioral dyscontrol, and polydipsia following right temporal lobe damage. J Am Acad Child Adolesc Psychiatry 1990; 29:472-474.
99. Friedman DL, Kastner T, Plummer AT, Ruiz MQ, Henning D. Adverse behavioral effects in individuals with mental retardation and mood disorders treated with carbamazepine. Am J Ment Retard 1992;96:541-546.
100. Gillham R, Baker G, Thompson P, et al. Standardisation of a self-report questionnaire for use in evaluating cognitive, affective and behavioural side-effects of anti-epileptic drug treatments. Epilepsy Res 1996;24:47-55.
101. Mathew G. Psychiatric symptoms associated with carbamazepine. BMJ (Clin Res Ed) 1988;296:1071.
102. McKee RJ, Larkin JG, Brodie MJ. Acute psychosis with carbamazepine and sodium valproate [letter]. Lancet 1989;1: 167.
103. Pleak RR, Birmaher B, Gavrilescu A, Abichandani C, Williams DT. Mania and neuropsychiatric excitation following carbamazepine. J Am Acad Child Adolesc Psychiatry 1988; 27:500-503.
104. Kessler AJ, Barklage NE, Jefferson JW. Mood disorders in the psychoneurologic borderland: three cases of responsiveness to carbamazepine. Am J Psychiatry 1989;146:81-83.
105. Neppe VM. Carbamazepine as adjunctive treatment in non-epileptic chronic inpatients with EEG temporal lobe abnormalities. J Clin Psychiatry 1983;44:326-331.
106. Smith DB, Mattson RH, Cramer JA, Collins JF, Novelly RA, Craft B. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 1987;28(suppl. 3):S50-58.
107. O'Dougherty M, Wright FS, Cox S, Walson P. Carbamazepine plasma concentration. Relationship to cognitive impairment. Arch Neurol 1987;44:863-867.
108. Gallassi R, Morreale A, Lorusso S, Procaccianti G, Lugaresi E, Baruzzi A. Carbamazepine and phenytoin. Comparison of cognitive effects in epileptic patients during monotherapy and withdrawal. Arch Neurol 1988;45:892-894.
109. Gillham RA, Williams N, Wiedmann K, Butler E, Larkin JG, Brodie MJ. Concentration-effect relationships with carbamazepine and its epoxide on psychomotor and cognitive function in epileptic patients. J Neurol Neurosurg Psychiatry 1988;51:929-933.
110. Brodie MJ, McPhail E, Macphee GJ, Larkin JG, Gray JM. Psychomotor impairment and anticonvulsant therapy in adult epileptic patients. Eur J Clin Pharmacol 1987;31:655-660.
111. Mitchell WG, Chavez JM. Carbamazepine versus phenobarbital for partial onset seizures in children. Epilepsia 1987;28: 56-60.
112. Forsythe I, Butler R, Berg I, McGuire R. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 1991;33:524-534.
113. Ketter TA, Malow BA, Flamini R, White SR, Post RM, Theodore WH. Carbamazepine withdrawal-emergent psychopathology [abstract]. Neurology 1993;43(suppl. 2):A194.
114. Bare MA. Nausea/vomiting associated with antiepileptic drug withdrawal [abstract]. Epilepsia 1998;39(suppl. 6):160-161.
115. McLean MJ, Macdonald RL. Sodium valproate, but not ethosuximide, produces use- and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J Pharmacol Exp Ther 1986; 237:1001-1011.
116. Franceschetti S, Hamon B, Heinemann U. The action of valproate on spontaneous epileptiform activity in the absence of synaptic transmission and on evoked changes in [Ca2+]o and [K+]o in the hippocampal slice. Brain Res 1986;386:1-11.
117. Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett 1990;116:233-238.
118. Schechter PJ, Tranier Y, Grove J. Effect of n-dipropylacetate on amino acid concentrations in mouse brain: correlations with anti-convulsant activity. J Neurochem 1978;31:1325-1327.
119. Löscher W. Effects of the antiepileptic drug valproate on metabolism and function of inhibitory and excitatory amino acids in the brain. Neurochem Res 1993;18:485-502.
120. Löscher W. Valproate induced changes in GABA metabolism at the subcellular level. Biochem Pharmacol 1981;30:1364-1366.
121. Löscher W. GABA in plasma, CSF and brain of dogs during acute and chronic treatment with gamma-acetylenic GABA and valproic acid. In: Okada Y, Roberts E, eds. Problems in GABA research: from brain to bacteria. Amsterdam: Excerpta Medica, 1982:102-109.
122. Taberner PV, Charington CB, Unwin JW. Effects of GAD and GABA-T inhibitors on GABA metabolism in vivo. Brain Res Bull 1980;5:621-625.
123. Gram L, Larsson OM, Johnsen AH, Schousboe A. Effects of valproate, vigabatrin and aminooxyacetic acid on release of endogenous and exogenous GABA from cultured neurons. Epilepsy Res 1988;2:87-95.
124. Whittle SR, Turner AJ. Effects of the anticonvulsant sodium valproate on gamma-aminobutyrate and aldehyde metabolism in ox brain. J Neurochem 1978;31:1453-1459.
125. Löscher W, Siemes H. Valproic acid increases gamma-aminobutyric acid in CSF of epileptic children. Lancet 1984; 2:225.
126. Löscher W, Schmidt D. Increase of human plasma GABA by sodium valproate. Epilepsia 1980;21:611-615.
127. Maitre M, Ciesielski L, Cash C, Mandel P. Comparison of the structural characteristics of the 4-aminobutyrate:2-oxoglutarate transaminases from rat and human brain, and of their affinities for certain inhibitors. Biochim Biophys Acta 1978;522:385-399.
128. Rasmussen KJ, Schneider HH, Petersen EN. Sodium valproate exerts anti-conflict activity in rats without any concomitant rise in forebrain GABA level. Life Sci 1981;29: 2163-2170.
129. Fernandez Teruel A, Boix F, Escorihuela RM, Yanez P, Tobena A. Sodium valproate reduces immobility in the behavioral 'despair' test in rats. Eur J Pharmacol 1988;152:1-7.
130. Boxer CM, Herzberg JL, Scott DF. Has sodium valproate hypnotic effects? Epilepsia 1976;17:367-370.
131. Herranz JL, Arteaga R, Armijo JA. Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients. Epilepsia 1982;23:203-214.
132. Marescaux C, Warter JM, Micheletti G, Rumbach L, Coquillat G, Kurtz D. Stuporous episodes during treatment with sodium valproate: report of seven cases. Epilepsia 1982;23: 297-305.
133. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327:765-771.
134. King JA, Swann AH, Samuel SR, Richardson SM, Stewart K, Couch JR. Long term weight gain (WG) associated with valproate in developmentally disabled (DD) and healthy adults (NA) [abstract]. Epilepsia 1998;39(suppl. 6):49.
135. Dean JC, Penry JK. Weight gain patterns in patients with epilepsy: comparison of antiepileptic drugs [abstract]. Epilepsia 1995;36(suppl. 4):72.
136. Prevey ML, Mattson RH, Cramer JA. Improvement in cognitive functioning and mood state after conversion to valproate monotherapy. Neurology 1989;39:1640-1641.
137. Stoll AL, Banov M, Kolbrener M, et al. Neurologic factors predict a favorable valproate response in bipolar and schizo-affective disorders. J Clin Psychopharmacol 1994;14:311-313.
138. Kastner T, Finesmith R, Walsh K. Long-term administration of valproic acid in the treatment of affective symptoms in people with mental retardation. J Clin Psychopharmacol 1993;13:448-451.
139. Husain SB, Wical BS. Adverse behavioral effects of valproate therapy in children with complex partial seizures [abstract]. Epilepsia 1998;39(suppl. 6):162.
140. Gallassi R, Morreale A, Lorusso S, Procaccianti G, Lugaresi E, Baruzzi A. Cognitive effects of valproate. Epilepsy Res 1990;5:160-164.
141. Aman MG, Werry JS, Paxton JW, Turbott SH. Effect of sodium valproate on psychomotor performance in children as a function of dose, fluctuations in concentration, and diagnosis. Epilepsia 1987;28:115-124.
142. Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994;35:381-390.
143. Leppik IE. Felbamate. Epilepsia 1995;36(suppl. 2):S66-72.
144. Pennell PB, Ogaily MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995;45:456-460.
145. White HS, Wolf HH, Swinyard EA, Skeen GA, Sofia RD. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia 1992;33:564-572.
146. Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A, Bernardi G. Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther 1996;277:121-127.
147. Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acid A receptors. Ann Neurol 1994;35:229-234.
148. White HS, Harmsworth WL, Sofia RD, Wolf HH. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 1995;20:41-48.
149. Wamsley JK, Sofia RD, Faull RL, Narang N, Ary T, McCabe RT. Interaction of felbamate with [3H]DCKA-labeled strychnine-insensitive glycine receptors in human postmortem brain. Exp Neurol 1994;129:244-250.
150. McCabe RT, Wasterlain CG, Kucharczyk N, Sofia RD, Vogel JR. Evidence for anticonvulsant and neuroprotectant action of felbamate mediated by strychnine-insensitive glycine receptors. J Pharmacol Exp Ther 1993;264:1248-1252.
151. Mele A, Thomas DN, Pert A. Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomotor activity. Neuroscience 1998;82:43-58.
152. Kass D. Differential response to anticonvulsants among bipolar patients. Curr Affect Illness 1994;13:1-2.
153. Asconapé JJ, Brotherton TA, Lauve LM, et al. Felbamate: efficacy and tolerability in patients with refractory epilepsies [abstract]. Epilepsia 1994;35(suppl. 8):114.
154. Baldwin MA, Cuestas M, Talwar D. Tolerability of felbamate in children [abstract]. Epilepsia 1994;35(suppl. 8):121.
155. King JA. Increased incidence of adverse behavioral side effects associated with the addition of felbamate (FBM) to antiepileptic drug (AED) regimens in the mentally retarded (MR) population [abstract]. Epilepsia 1994;35(suppl. 8):94.
156. Osorio I, Lai CW, Lai YHC, Manna B, O'Brien C. Felbamate-induced adverse side effects [abstract]. Epilepsia 1994; 35(suppl. 8):115.
157. Spitz MC, Towbin J, Shantz D. Felbamate: initial experience in adults with epilepsy [abstract]. Epilepsia 1994;35(suppl. 8):95.
158. Faught E, Kuzniecky R, Thompson G. Tolerability of high dose felbamate [abstract]. Epilepsia 1994;35(suppl. 8):32.
159. Woodhams KA, Bennett B, Bronstein KS, Anaizi N, Erba G, Berg MJ. Behavioral changes in individuals treated with felbamate [abstract]. Epilepsia 1994;35(suppl. 8):160.
160. Ketter TA, Malow BA, Flamini R, et al. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res 1996;23:129-137.
161. Kanner AM, Ristanovic R, Smith M, Bergen D, Pierre-Louis SJC, Frey M. Acute depressive disorder following a three week switch-over to felbamate: a controlled study [abstract]. Epilepsia 1994;35(suppl. 8):95.
162. Theodore WH, Albert P, Stertz B, et al. Felbamate monotherapy: implications for antiepileptic drug development. Epilepsia 1995;36:1105-1110.
163. Wilder BJ, Campbell KW, Uthman BM, Gilmore RL, Barber CP, Hargrove SC. Felbamate for intractable epilepsy: a long term study [abstract]. Epilepsia 1991;32(suppl. 3):59.
164. Mason SL. Psychological disturbances as a contributing factor for felbamate discontinuation [abstract]. Epilepsia 1994; 35(suppl. 8):32.
165. Liporace J, Roberts D, Sperling M, French J, Dichter M. Post-marketing felbamate experience [abstract]. Epilepsia 1994;35(suppl. 8):55.
166. McConnell H, Snyder PJ, Duffy JD, et al. Neuropsychiatric side effects related to treatment with felbamate. J Neuropsychiatry Clin Neurosci 1996;8:341-346.
167. Zagnoni PG. Felbamate efficacy and tolerability: a multicenter study [abstract]. Epilepsia 1997;38(suppl. 3):69.
168. Hill RR, Stagno SJ, Tesar GE. Secondary mania associated with the use of felbamate. Psychosomatics 1995;36:404-406.
169. Bourgeois B, Leppik IE, Sackellares JC, et al. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993;43:693-696.
170. Knable MB, Rickler K. Psychosis associated with felbamate treatment [letter]. J Clin Psychopharmacol 1995;15:292-293.
171. Wolff DL. Post-market felbamate use in the refractory epilepsy population [abstract]. Epilepsia 1994;35(suppl. 8):32.
172. Luciano D, Devinsky O, Raguthu S, Kutscher M, Frontera A. Movement disorders during felbamate therapy [abstract]. Epilepsia 1994;35(suppl. 8):159.
173. Carson D, Nagarajan L, Solomon G, Labar DR. Safety profile of felbamate in children under the age of four with refractory epilepsy [abstract]. Epilepsia 1994;35(suppl. 8):121.
174. Gay PE, Mecham GF, Coskey JS, Sadler T, Thompson JA. Behavioral effects of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). Psychol Rep 1995;77: 1208-1210.
175. Hipp KK, Frisbie JA, Gilmartin RC, Rawlings P, Islam S. Felbatol: benefits vs. risks [abstract]. Epilepsia 1995; 36(suppl. 4):66.
176. Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993;34:S18-24.
177. Ritter FJ, Leppik IE, Dreifuss FE, et al. The Felbamate Study Group in Lennox-Gastaut Syndrome: efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328:29-33.
178. Beard WJ, Free SM Jr. Two double-blind, controlled studies comparing chlorethate, a new sedative-tranquilizer, with meprobamate and with phenobarbital. J Clin Pharmacol J New Drugs 1967;7:41-45.
179. Gotz E, Feuerstein TJ, Lais A, Meyer DK. Effects of gabapentin on release of gamma-aminobutyric acid from slices of rat neostriatum. Arzneimittelforschung 1993;43:636-638.
180. Su TZ, Lunney E, Campbell G, Oxender DL. Transport of gabapentin, a gamma-amino acid drug, by system L alpha-amino acid transporters: a comparative study in astrocytes, synaptosomes, and CHO cells. J Neurochem 1995;64:2125-2131.
181. Petroff OAC, Hyder F, Rothman DL, Collins TL, Mattson RH. Gabapentin increases human brain GABA within one hour [abstract]. Epilepsia 1998;39(suppl. 6):71.
182. Petroff OA, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996;39:95-99.
183. Taylor CP, Gee NS, Su TZ, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998; 29:233-249.
184. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:829-841.
185. Hill DR, Suman-Chauhan N, Woodruff GN. Localization of [3H]gabapentin to a novel site in rat brain: autoradiographic studies. Eur J Pharmacol 1993;244:303-309.
186. Gee NS, Brown JP, Dissanayake VU, Offord J, Thurlow K, Woodruff GN. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-5776.
187. Reimann W. Inhibition by GABA, baclofen and gabapentin of dopamine release from rabbit caudate nucleus: are there common or different sites of action? Eur J Pharmacol 1983; 94:341-344.
188. Schlicker E, Reimann W, Gothert M. Gabapentin decreases monoamine release without affecting acetylcholme release in the brain. Arzneimittelforschung 1985;35:1347-1349.
189. Watson WP, Robinson E, Little HJ. The novel anticonvulsant gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal syndrome. Neuropharmacology 1997;36:1369-1375.
190. Pande AC, Davidson JRT, Greist JH, Jefferson JW, Weisler R, Sutherland S. A placebo-controlled study of gabapentin in social phobia [abstract]. 36th Ann Meet Am Coll Neuropsychopharmacol 1997;141.
191. Crockatt JG, Greiner M, Clift LL, Pande AC. Treatment of panic disorder with gabapentin [abstract]. Proc 38th Ann Meet New Clin Drug Evaluation Unit Prog 1998;154.
192. Frye MA, Ketter TA, Osuch EA, Kimbrell T, Speer AM, Dunn RT, Post RM. Gabapentin and lamotrigine monotherapy in mood disorder: an update [abstract]. Proc 151st Ann Meet Am Psychiatric Assoc 1998;150.
193. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-880.
194. Asconape J, Collins T. Weight gain associated with the use of gabapentin [abstract]. Epilepsia 1995;36(suppl. 4):72.
195. King JA, Bayles RL. Weight gain during add-on therapy using gabapentin (GBP) [abstract]. Epilepsia 1995;36(suppl. 4):72.
196. Cahill WT, Mozahem K, Privitera MD. Weight changes with the use of gabapentin [abstract]. Epilepsia 1998;39(suppl. 6):54.
197. Dimond KR, Pande AC, Lamoreaux L, Pierce MW. Effect of gabapentin (Neurontin) on mood and well-being in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:407-417.
198. Harden CL, Pick LH. Alterations in mood and anxiety in epilepsy patients treated with gabapentin [abstract]. Epilepsia 1996;37(suppl. 5):137.
199. Hayes A, Mann M, Greeley C, et al. An ongoing open-label multicenter study evaluating gabapentin (Neurontin) monotherapy and safety in patients with medically refractory partial seizures [abstract]. Epilepsia 1994;35(suppl. 8):164.
200. Crockatt JG, Leiderman DB, Malicsi MJR, Garofalo EA. Open-label follow-on study of gabapentin (GBP; Neurontin) monotherapy in patients with refractory epilepsy [abstract]. Epilepsia 1995;36(suppl. 4):69.
201. Muscas GC, Chiaramonti R, Borgheresi A, et al. Long-term cognitive and mood effects of gabapentin [abstract]. Epilepsia 1997;38(suppl. 3):35.
202. Hauck A, Bhaumik S. Hypomania induced by gabapentin [letter]. Br J Psychiatry 1995;167:549.
203. Short C, Cooke L. Hypomania induced by gabapentin [letter]. Br J Psychiatry 1995;166:679-680.
204. Cugley AL, Swartz BE. Gabapentin-associated mood changes [abstract]. Epilepsia 1995;36(suppl. 4):72.
205. Doherty KP, Gates JR, Penovich PE, Moriarty GL. Gabapentin in a medically refractory epilepsy population: seizure responses and unusual side effects [abstract]. Epilepsia 1995; 36(suppl. 4):71.
206. Litzinger MJ, Wiscombe N, Hanny A, Yau J, Green D. Increased seizures and aggression seen in persons with mental retardation and epilepsy treated with Neurontin [abstract]. Epilepsia 1995;36(suppl. 4):71.
207. Shantz D, Towbin JA, Spitz MC. Changes in mood and affect in patients on gabapentin [abstract]. Epilepsia 1995; 36(suppl. 4):73.
208. Wolf SM, Shinnar S, Kang H, Gil KB, Moshe SL. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995;36:1203-1205.
209. Zupanc ML, Schroeder VM. Behavioral changes in children on gabapentin [abstract]. Epilepsia 1995;36(suppl. 4):73.
210. Lee DO, Steingard RJ, Cesena M, Helmers SL, Riviello JJ, Mikati MA. Behavioral side effects of gabapentin in children. Epilepsia 1996;37:87-90.
211. Tallian KB, Nahata MC, Lo W, Tsao CY. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996;37:501-502.
212. Bhaumik S, Branford D, Duggirala C, Ismail IA. A naturalistic study of the use of vigabatrin, lamotrigine and gabapentin in adults with learning disabilities. Seizure 1997;6:127-133.
213. Dodrill CB, Arnett JL, Garofalo EA, Slenk C, Hes MS, Pierce MW. Cognitive and quality-of-life effects of long-term gabapentin administration [abstract]. Epilepsia 1997;38(suppl. 8): 92-93.
214. Meador KJ, Loring DW, Ray PG, et al. Cognitive effects of carbamazepine and gabapentin [abstract]. Epilepsia 1998; 39(suppl. 6):216.
215. Cheung H, Kamp D, Harris E. An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels. Epilepsy Res 1992;13:107-112.
216. Leach MJ, Lees G, Riddall DR. Lamotrigine: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995:861-869.
217. Waldmeier PC, Baumann PA, Wicki P, Feldtrauer JJ, Stierlin C, Schmutz M. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Neurology 1995;45: 1907-1913.
218. Anand A, Charney DS, Cappiello A, Berman RM, Oren DA, Krystal JH. Lamotrigine reduces the psychotomimetic - but not the mood elevating-effects of ketamine in humans [abstract]. Proc 36th Ann Meet Am Coll Neuropsychopharmacol 1997;251.
219. Critchley MAE. Effects of lamotrigine (Lamictal) in an animal model of anxiety [abstract]. Br J Pharmacol 1994;111: 205P.
220. Calabrese JR, Bowden CL, Sachs GS, Asher JA, Monaghan E, Rudd D. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999;60:79-88.
221. Schacter S, Leppik I, Matsuo F, Messenheimer JA, Faught E, Risner ME. Lamotrigine: six month, placebo-controlled safety and tolerance study. J Epilepsy 1995;8:201-210.
222. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995;345:476-479.
223. Bergen D, Ristanovic R, Rudd D, Dren AT, Klein K. Placebo-controlled evaluation of clinical laboratory data and body weight during administration of Lamictal (lamotrigine) in outpatients with partial seizures [abstract]. Epilepsia 1994; 35(suppl. 8):163.
224. Betts T, Goodwin G, Withers RM, Yuen AW. Human safety of lamotrigine. Epilepsia 1991;32:S17-21.
225. Isojarvi JI, Rattya J, Myllyla VV, et al. Valproate lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998;43:446-451.
226. Carwile ST, Husain AM, Miller PP, Radtke RA. Lamotrigine and sexual dysfunction in male patients with epilepsy [abstract]. Epilepsia 1997;38(suppl. 8):180.
227. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43:2284-2291.
228. Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34:312-322.
229. Davanzo PA, King BH. Open trial lamotrigine in the treatment of self-injurious behavior in an adolescent with profound mental retardation. J Child Adolesc Psychopharmacol 1996;6:273-279.
230. Jacoby A, Baker G, Bryant-Comstock L, Phillips S, Bamford C. Lamotrigine add-on therapy is associated with improvement in mood in patients with severe epilepsy [abstract]. Epilepsia 1996;37(suppl. 5):202.
231. Schapel G, Chadwick D. A survey comparing lamotrigine and vigabatrin in everyday clinical practice. Seizure 1996;5:267-270.
232. Maxoutova E. Lamotrigine: perspectives of use in psychiatry [abstract]. Epilepsia 1997;38(suppl. 3):66.
233. Pelliccia A, Cerquiglini A, Ferreli S, Ottaviano P. Behavioral improvement in children treated with lamotrigine [abstract]. Epilepsia 1997;38(suppl. 3):130.
234. Serra LL, Gallicchio B, Serra FP. Lamotrigine monotherapy for treatment of learning and behavioral disorders in epileptic children [abstract]. Epilepsia 1997;38(suppl. 3):130-131.
235. McKee JR, Sunder TR, Vuong A, Hammer AE. Effects of Lamictal (LTG) adjunctive therapy in the mentally retarded patients with epilepsy: an interim analysis [abstract]. Epilepsia 1998;39(suppl. 6):130.
236. Sorenson T, May J, Mogens FL. Long-time follow-up on lamotrigine in the treatment of epilepsy in the mentally retarded [abstract]. Epilepsia 1998;39(suppl. 6):130.
237. Beran RG, Gibson RJ. Aggression provoked by lamotrigine in patients with developmental delay [abstract]. Epilepsia 1997;38(suppl. 3):68.
238. Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39:874-877.
239. Martin M, Munoz-Blanco JL, Lopez-Ariztegui N. Acute psychosis induced by lamotrigine [abstract]. Epilepsia 1995; 36(suppl. 3):S118.
240. De Leon OA, Furmaga K. Lamotrigine in the treatment of epileptic psychosis [abstract]. Proc 151st Ann Meet Am Psychiatric Assoc 1998;148-149.
241. Aldenkamp AP, Mulder OG, Overweg J. Cognitive effects of lamotrigine as first-line add-on in patients with localization-related (partial) epilepsy. J Epilepsy 1997;10:117-121.
242. Banks GK, Beran RG. Neuropsychological assessment in lamotrigine treated epileptic patients. Clin Exp Neurol 1991; 28:230-237.
243. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997;231:123-126.
244. Zhang X, Velumian AA, Jones OT, Carlen PT. Topiramate reduces high-voltage activated calcium currents in CA1 pyramidal neurons in vitro [abstract]. Epilepsia 1998;39(suppl. 6):44.
245. Severt L, Coulter DA, Sombati S, DeLorenzo RJ. Topiramate selectively blocks kainate currents in cultured hippocampal neurons [abstract]. Epilepsia 1995;36(suppl. 4):38.
246. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;28:167-179.
247. Maryanoff BE, Costanzo MJ, Nortey SO, et al. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives. J Med Chem 1998;41:1315-1343.
248. Kuzniecky R, Hetherington H, Ho S, et al. Topiramate increases cerebral GABA in healthy humans. Neurology 1998; 51:627-629.
249. Kuzniecky RI, Hetherington H, Ho S, et al. Topiramate increases cerebral GABA concentrations in healthy adults in the acute and chronic states [abstract]. Epilepsia 1998; 39(suppl. 6):71.
250. Calabrese JR, Shelton MD III, Keck PE Jr, McElroy SL, Werkner JE. Topiramate in severe treatment-refractory mania [abstract]. Proc 151st Ann Meet Am Psychiatric Assoc 1998;121-122.
251. Marcotte D, Gullick E, van Kammen DP. Use of topiramate, a new antiepileptic drug, as a mood stabilizer [abstract]. Proc 37th Ann Meet Am Coll Neuropsychopharmacology 1998;116.
252. Suppes T, Brown ES, McElroy SL, et al. A pilot trial of adjunctive topiramate in the treatment of bipolar disorder: application of the Stanley Foundation Bipolar Network (SFBN) prospective protocol [abstract]. Proc 37th Ann Meet Am Coll Neuropsychopharmacology 1998;306.
253. Edwards K, Norton J, Potter D. Assessment of efficacy and tolerability of topiramate in slow versus rapid titration [abstract]. Epilepsia 1997;38(suppl. 3):59.
254. Gilliam FG, Veloso F, Schwabe S, Pledger G, Wu SC. Seizure freedom with topiramate: results from an open-label follow-on to a double-blind titration study [abstract]. Epilepsia 1998;39(suppl. 6):56.
255. Shorvon SD. Safety of topiramate: adverse events and relationships to dosing. Epilepsia 1996;37(suppl. 2):S18-22.
256. Tassinari CA, Michelucci R, Chauvel P, et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37: 763-768.
257. Abou-Khalil B, Fakhoury T. Neuropsychiatric profile of high-dose topiramate [abstract]. Epilepsia 1997;38(suppl. 8):207.
258. Betts T, Smith K, Khan G. Severe psychiatric reactions to topiramate [abstract]. Epilepsia 1997;38(suppl. 3):64.
259. Sharief M, Viteri C, Ben-Menachem E, et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 1996;25:217-224.
260. Thaneder S, Rosenfeld WE. Topiramate well tolerated by pediatric patients [abstract]. Epilepsia 1995;36(suppl. 4):34.
261. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 1996;46:1678-1683.
262. Tartara A, Sartori I, Manni R, Galimberti CA, Di Fazio M, Perucca E. Efficacy and safety of topiramate in refractory epilepsy: a long-term prospective trial. Ital J Neurol Sci 1996;17:429-432.
263. Bittermann HJ, Steinhoff BJ. Topiramate - an effective new anticonvulsant. An open prospective study. Nervenarzt 1997; 68:836-838.
264. Fowler M, Besag FMC, Strange M, Pool F. Effects of topiramate on behavior in adolescents with learning disabilities [abstract]. Epilepsia 1997;38(suppl. 3):131.
265. Glauser TA. Preliminary observations on topiramate in pediatric epilepsies. Epilepsia 1997;38(suppl. 1):S37-41.
266. Faught E, French J, Harden C, Glaun B, Khan A. Adverse effects of topiramate: results from a large postmarketing survey [abstract]. Epilepsia 1997;38(suppl. 8):97-98.
267. Khan A, Faught E, Kuzniecky R, Gilliam F, Laich E. Acute psychotic symptoms induced by topiramate [abstract]. Epilepsia 1997;38(suppl. 8):97.
268. Dohmeier C, Kay A, Greathouse N. Neuropsychiatric complications of topiramate therapy [abstract]. Epilepsia 1998; 39(suppl. 6):189.
269. Tatum WO IV, French JA, Faught E, Williams SF, Privitera M. Postmarketing experience with topiramate and cognition [abstract]. Epilepsia 1998;39(suppl. 6):56.
270. Sinclair KR, Martin R, Kuzniecky R, et al. Comparative cognitive effects of topiramate, gabapentin, and lamotrigine: an acute and steady-state dosing study in healthy volunteers [abstract]. Epilepsia 1998;39(suppl. 6):250.
271. Suzdak PD, Jansen JA. A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia 1995;36:612-626.
272. Borden LA, Murali Dhar TG, Smith KE, Weinshank RL, Branchek TA, Gluchowski C. Tiagabine, SK&F 89976-A, CI-966 and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur J Pharmacol 1994;269:219-224.
273. Sybirska E, Seibyl JP, Bremner JD, et al. [123I]iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain. Neuropharmacology 1993;32:671-680.
274. Gao XM, Kakigi T, Friedman MB, Tamminga CA. Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. J Neural Transm [Gen Sect] 1994;95:63-69.
275. Nielsen EB, Suzdak PD, Andersen KE, Knutsen LJ, Sonnewald U, Braestrup C. Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991;196:257-266.
276. Kaufman KR. Adjunctive tiagabine treatment of psychiatric disorders: three cases. Ann Clin Psychiatry 1998;10:181-4.
277. Leppik IE. Tiagabine: the safety landscape. Epilepsia 1995; 36(suppl. 6):S10-13.
278. Hogan RE, Lenz GT, Deaton R, Sommerville KW. Weight changes with adjunctive therapy of phenytoin, carbamazepine or tiagabine in a multicenter trial of partial seizures [abstract]. Epilepsia 1998;39(suppl. 6):125.
279. Schacter S, Ringham G, Pixton G, Chang S, Sommerville KW. Premature discontinuations in tiagabine clinical trials [abstract]. Epilepsia 1994;35(suppl. 8):93.
280. Leppik I, Sachdeo RC, Schacter S, et al. Long term safety of tiagabine HCI. Epilepsia 1994;35(suppl. 8):144.
281. Dodrill CB, Arnett JL, Sommerville KW, Shu V. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997;48:1025-1031.
282. Sveinbjornsdottir S, Sander JW, Patsalos PN, Upton D, Thompson PJ, Duncan JS. Neuropsychological effects of tiagabine, a potential new antiepileptic drug. Seizure 1994;3: 29-35.
283. Sackellares JC, Deaton R, Sommerville KW. Incidence of psychosis in controlled tiagabine (Gabitril™) trials [abstract]. Epilepsia 1997;38(suppl. 3):67.
284. Trimble MR, O'Donoghue M, Sander L, Duncan J. Psychosis with tiagabine [abstract]. Epilepsia 1997;38(suppl. 3):40-41.
285. Cramer J, Bagnall J, Chang J, Sommerville KW. Short-term change in quality of life when tiagabine or standard medication is added to carbamazepine or phenytoin [abstract]. Epilepsia 1998;39(suppl. 6):188.
286. Dodrill CB, Arnett J, Deaton R, Lenz GT, Sommerville KW. Adjunctive tiagabine, phenytoin, and carbamazepine and neuropsychological tests in a multicenter trial for partial seizures [abstract]. Epilepsia 1998;39(suppl. 6):147.
287. Dodrill CB, Arnett JL, Shu V, Pixton GC, Lenz GT, Sommerville KW. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998;39:33-42.
288. Alto G, Chang S, Sommerville KW. Use of the Costart term "thinking abnormal" in a multicenter trial of tiagabine for partial epilepsy [abstract]. Epilepsia 1994;35(suppl. 8):116.